Portal de Periódicos da CAPES

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

2015; American Association for Cancer Research; Volume: 3; Issue: 5 Linguagem: Inglês

10.1158/2326-6066.cir-15-0064

2326-6074

Leisha A. Emens, Gary Middleton,

Immune Cell Function and Interaction

Abstract Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted that certain chemotherapies can augment tumor immunity. The recent success of immune checkpoint inhibitors has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity. Two major ways that chemotherapy promotes tumor immunity are by inducing immunogenic cell death as part of its intended therapeutic effect and by disrupting strategies that tumors use to evade immune recognition. This second strategy, in particular, is dependent on the drug, its dose, and the schedule of chemotherapy administration in relation to antigen exposure or release. In this Cancer Immunology at the Crossroads article, we focus on cancer vaccines and immune checkpoint blockade as a forum for reviewing preclinical and clinical data demonstrating the interplay between immunotherapy and chemotherapy. Cancer Immunol Res; 3(5); 436–43. ©2015 AACR.